Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
- Issued Date
- 2020
- Type
- Article
- Publisher
- LANCET ONCOLOGY
- Language
- 영어
- ISSN
- 1470-2045
- Citation Volume
- 21
- Citation Number
- 12
- Citation Start Page
- 1574
- Citation End Page
- 1588
- 파일 목록
-
-
관련 파일이 존재하지 않습니다.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.